Evidence map›Paper›PMID 23346164›Full record

ArticleJournal of breast cancer2012

Seroma formation after breast cancer surgery: what we have learned in the last two decades.

Vivek Srivastava, Somprakas Basu, Vijay Kumar Shukla

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Journal of breast cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 116 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 7 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03784859 completednot on this mapstarted 2019, after this paper: background citation

Tissue Expansion in Breast Reconstruction Without Drains: A Study Using a Tissue Expander That Collects Periprosthetic Fluid

TypeobservationalSponsorCedars-Sinai Medical CenterRan2019 to 2020Enrolled5ConditionsBreast Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Breast Implant, ComplicationsArmsInsertion of Tissue Expander with Fluid Reservoir
NCT05280353 narecruitingnot on this mapstarted 2022, after this paper: background citation

Seroma Control in Axillary Lymphadenectomy With Glubran 2® Without Drain. Multicenter, Prospective, Randomized Clinical Trial. GALA-ND Study (Glu Axillary Lymphadenectomy Ambulatory- no Drain)

TypeinterventionalSponsorOmphis FoundationRan2022 to 2026Enrolled134ConditionsSeroma Following ProcedureArmsGlubran 2
NCT07607366 narecruitingnot on this mapstarted 2025, after this paper: background citation

Is Negative Pressure Wound Therapy Associated With a Decreased Risk of Postoperative Seroma in Breast Cancer Patients Who Have Undergone Mastectomy?

TypeinterventionalSponsorDalarna County Council, SwedenRan2025 to 2027Enrolled76ConditionsBreast Cancer - FemaleArmsPICO negative pressure wound therapy by Smith and Nephew
3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 7 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Prevention of Post-Mastectomy Seroma in Breast Cancer Patients:Sultan Qaboos University medical journal · 2025
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Vivek SrivastavaDepartment of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Somprakas Basu
Vijay Kumar Shukla
Banaras Hindu University · INInstitute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Formation of a seroma most frequently occurs after mastectomy and axillary surgery. Prolonged drainage is troublesome as it increases the risk for infection and can significantly delay adjuvant therapy. Seroma has been defined as serous fluid collection under the skin flaps or in the axillary dead space following mastectomy and/or axillary dissection. Because the true etiology of a seroma is unknown, a multifactorial-causation hypothesis has been accepted. Surgical factors include technique, extent of dissection and the surgical devices used for dissection. Obliteration of dead space with various flap fixation techniques, use of sclerosants, fibrin glue and sealants, octreotide, and pressure garments have been attempted with conflicting results and none have been consistent. Early movement of the shoulder during the postoperative period may increase the formation of seroma, although delayed physiotherapy decreases the formation of seroma. A detailed analysis of the use of drains showed that use of single or multiple drains, early or late removal, and drains with or without suction are not significantly different for the incidence of seroma. Although there is evidence for reduced seroma formation after early drain removal, very early removal within 24 hours seems to increase formation of seroma. No patient or tumor factors seem to affect seroma formation except body mass index and body weight. Consensus is lacking among studies/trials with different groups producing conflicting evidence. Besides a few established factors such as body mass index, the use of electrocautery for dissection, early drain removal, low vacuum drains, obliteration of dead space, and delayed shoulder physiotherapy, most of the hypothesized causes have not been demonstrated consistently. Thus, seroma remains a threat to both the patient and surgeon. Recurrent transcutaneous aspiration remains the only successful management.

Indexed as

Breast neoplasmsLymph node excisionMastectomySeroma

Identifiers

PMID23346164
PMCPMC3542843
OpenAlexW2060256122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.